TW200410699A - Use of ANECORTAVE acetate for the protection of visual acuity in patients with age related macular degeneration - Google Patents
Use of ANECORTAVE acetate for the protection of visual acuity in patients with age related macular degeneration Download PDFInfo
- Publication number
- TW200410699A TW200410699A TW092118474A TW92118474A TW200410699A TW 200410699 A TW200410699 A TW 200410699A TW 092118474 A TW092118474 A TW 092118474A TW 92118474 A TW92118474 A TW 92118474A TW 200410699 A TW200410699 A TW 200410699A
- Authority
- TW
- Taiwan
- Prior art keywords
- patients
- pharmaceutical composition
- placebo
- vision
- acetate
- Prior art date
Links
- 230000004304 visual acuity Effects 0.000 title claims abstract description 33
- 206010064930 age-related macular degeneration Diseases 0.000 title claims description 34
- 208000002780 macular degeneration Diseases 0.000 title claims description 32
- YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave acetate Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 title abstract description 8
- 229960001232 anecortave Drugs 0.000 title abstract 7
- 239000003814 drug Substances 0.000 claims abstract description 18
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 42
- 210000003786 sclera Anatomy 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 238000003860 storage Methods 0.000 claims description 10
- 230000001771 impaired effect Effects 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 5
- 239000007943 implant Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 9
- -1 acetate compound Chemical class 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 239000000902 placebo Substances 0.000 abstract description 48
- 229940068196 placebo Drugs 0.000 abstract description 48
- 230000004438 eyesight Effects 0.000 abstract description 33
- 208000005590 Choroidal Neovascularization Diseases 0.000 abstract description 28
- 206010060823 Choroidal neovascularisation Diseases 0.000 abstract description 28
- 230000008859 change Effects 0.000 abstract description 21
- 238000011282 treatment Methods 0.000 abstract description 18
- 229940079593 drug Drugs 0.000 abstract description 15
- 230000003902 lesion Effects 0.000 abstract description 9
- 230000005764 inhibitory process Effects 0.000 abstract description 7
- 239000004037 angiogenesis inhibitor Substances 0.000 abstract description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 abstract description 4
- 238000002347 injection Methods 0.000 abstract description 3
- 239000007924 injection Substances 0.000 abstract description 3
- 230000004377 improving vision Effects 0.000 abstract description 2
- 238000004321 preservation Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 42
- 238000002474 experimental method Methods 0.000 description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 35
- 201000010099 disease Diseases 0.000 description 30
- 238000004458 analytical method Methods 0.000 description 25
- 230000004393 visual impairment Effects 0.000 description 23
- 201000004569 Blindness Diseases 0.000 description 20
- 238000002560 therapeutic procedure Methods 0.000 description 20
- 230000000007 visual effect Effects 0.000 description 13
- 230000014759 maintenance of location Effects 0.000 description 12
- 230000033115 angiogenesis Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 210000001525 retina Anatomy 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 150000003431 steroids Chemical class 0.000 description 6
- 208000002177 Cataract Diseases 0.000 description 5
- 238000002583 angiography Methods 0.000 description 5
- 230000006866 deterioration Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000009097 single-agent therapy Methods 0.000 description 5
- 230000009978 visual deterioration Effects 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 230000000964 angiostatic effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 229940000406 drug candidate Drugs 0.000 description 4
- 239000003777 experimental drug Substances 0.000 description 4
- 230000000649 photocoagulation Effects 0.000 description 4
- 231100000279 safety data Toxicity 0.000 description 4
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000002428 photodynamic therapy Methods 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 3
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 2
- 102000009840 Angiopoietins Human genes 0.000 description 2
- 108010009906 Angiopoietins Proteins 0.000 description 2
- 206010010719 Conjunctival haemorrhage Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010015911 Eye burns Diseases 0.000 description 2
- 206010015958 Eye pain Diseases 0.000 description 2
- 206010015995 Eyelid ptosis Diseases 0.000 description 2
- 206010024214 Lenticular opacities Diseases 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000003161 choroid Anatomy 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000010595 endothelial cell migration Effects 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 208000018769 loss of vision Diseases 0.000 description 2
- 231100000864 loss of vision Toxicity 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- 201000003004 ptosis Diseases 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- DZSVIVLGBJKQAP-UHFFFAOYSA-N 1-(2-methyl-5-propan-2-ylcyclohex-2-en-1-yl)propan-1-one Chemical compound CCC(=O)C1CC(C(C)C)CC=C1C DZSVIVLGBJKQAP-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 201000009487 Amblyopia Diseases 0.000 description 1
- 102000012936 Angiostatins Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100031900 Neogenin Human genes 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 238000001358 Pearson's chi-squared test Methods 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000002154 Pterygium Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 102000007451 Steroid Receptors Human genes 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- CPCNAMNNSLASDC-UHFFFAOYSA-N acetic acid;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound CC(O)=O.CN1CCCC1C1=CC=CN=C1 CPCNAMNNSLASDC-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000003023 adrenocorticotropic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 238000013176 antiplatelet therapy Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 108091008723 corticosteroid receptors Proteins 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008773 effect on children Effects 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 238000013534 fluorescein angiography Methods 0.000 description 1
- 239000001046 green dye Substances 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 108010076969 neogenin Proteins 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000022749 pupil disease Diseases 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
- 206010055031 vascular neoplasm Diseases 0.000 description 1
- YTZALCGQUPRCGW-ZSFNYQMMSA-N verteporfin Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(CCC(=O)OC)=C(C)C(N3)=C3)=N2)C)=C(C=C)C(C)=C1C=C1C2=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@@]2(C)C3=N1 YTZALCGQUPRCGW-ZSFNYQMMSA-N 0.000 description 1
- 229940061392 visudyne Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40122002P | 2002-08-05 | 2002-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200410699A true TW200410699A (en) | 2004-07-01 |
Family
ID=31495940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW092118474A TW200410699A (en) | 2002-08-05 | 2003-07-07 | Use of ANECORTAVE acetate for the protection of visual acuity in patients with age related macular degeneration |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20040127472A1 (https=) |
| EP (1) | EP1539182A4 (https=) |
| JP (1) | JP2005535691A (https=) |
| KR (1) | KR20050026510A (https=) |
| CN (1) | CN1674913A (https=) |
| AR (1) | AR040599A1 (https=) |
| AU (1) | AU2003281817A1 (https=) |
| BR (1) | BR0313546A (https=) |
| CA (1) | CA2494211A1 (https=) |
| DE (1) | DE03742226T1 (https=) |
| ES (1) | ES2244361T1 (https=) |
| MX (1) | MXPA05000773A (https=) |
| PL (1) | PL375024A1 (https=) |
| RU (1) | RU2322239C2 (https=) |
| TW (1) | TW200410699A (https=) |
| WO (1) | WO2004012742A1 (https=) |
| ZA (1) | ZA200500731B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040127472A1 (en) * | 2002-08-05 | 2004-07-01 | Jerdan Janice A. | Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration |
| MXPA05008396A (es) * | 2003-02-20 | 2006-03-30 | Alcon Inc | Formulaciones de glucocorticoides para tratar angiogenesis ocular patologica. |
| AU2004249256A1 (en) * | 2003-06-20 | 2004-12-29 | Alcon, Inc. | Treatment of AMD with combination of ingredients |
| CA2539023A1 (en) * | 2003-09-23 | 2005-04-14 | Alcon Inc. | Triamcinolone acetonide and anecortave acetate formulations for injection |
| US7257366B2 (en) * | 2003-11-26 | 2007-08-14 | Osmosis Llc | System and method for teaching a new language |
| WO2005110374A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
| US20070059336A1 (en) * | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
| US7261529B2 (en) * | 2005-09-07 | 2007-08-28 | Southwest Research Institute | Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents |
| US7758778B2 (en) * | 2005-09-07 | 2010-07-20 | Southwest Research Institute | Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents |
| US9693967B2 (en) * | 2005-09-07 | 2017-07-04 | Southwest Research Institute | Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates |
| US20070134244A1 (en) * | 2005-10-14 | 2007-06-14 | Alcon, Inc. | Combination treatment for pathologic ocular angiogenesis |
| MX2009006146A (es) * | 2006-12-18 | 2009-06-19 | Alcon Res Ltd | Dispositivos y metodos para la administracion de farmacos oftalmicos. |
| CN101759741B (zh) * | 2008-11-06 | 2013-01-09 | 天津金耀集团有限公司 | 一种化合物及其在制备治疗血管新生的药物中的应用 |
| CN101923856B (zh) | 2009-06-12 | 2012-06-06 | 华为技术有限公司 | 语音识别训练处理、控制方法及装置 |
| US20150037422A1 (en) * | 2012-02-22 | 2015-02-05 | Trustees Of Tufts College | Compositions and methods for ocular delivery of a therapeutic agent |
| RU2489146C1 (ru) * | 2012-07-11 | 2013-08-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) | Способ лечения "сухой" формы возрастной макулярной дегенерации |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4876250A (en) * | 1988-10-31 | 1989-10-24 | Alcon Laboratories, Inc. | Methods for controlling ocular hypertension with angiostatic steroids |
| RU2051651C1 (ru) * | 1988-07-07 | 1996-01-10 | Институт химии поверхности АН Украины | Основа для глазных капель |
| US5371078A (en) * | 1988-10-31 | 1994-12-06 | Alcon Laboratories, Inc. | Angiostatic steroids and methods and compositions for controlling ocular hypertension |
| US5770592A (en) * | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
| US5679666A (en) * | 1991-11-22 | 1997-10-21 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids |
| ATE283013T1 (de) * | 1999-10-21 | 2004-12-15 | Alcon Inc | Medikamentenzuführvorrichtung |
| US6416777B1 (en) * | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| US20040127472A1 (en) * | 2002-08-05 | 2004-07-01 | Jerdan Janice A. | Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration |
| US20070134244A1 (en) * | 2005-10-14 | 2007-06-14 | Alcon, Inc. | Combination treatment for pathologic ocular angiogenesis |
-
2003
- 2003-06-26 US US10/606,501 patent/US20040127472A1/en not_active Abandoned
- 2003-06-26 PL PL03375024A patent/PL375024A1/xx unknown
- 2003-06-26 JP JP2004526013A patent/JP2005535691A/ja active Pending
- 2003-06-26 MX MXPA05000773A patent/MXPA05000773A/es not_active Application Discontinuation
- 2003-06-26 US US10/521,707 patent/US20060166956A1/en not_active Abandoned
- 2003-06-26 DE DE03742226T patent/DE03742226T1/de active Pending
- 2003-06-26 KR KR1020057001248A patent/KR20050026510A/ko not_active Ceased
- 2003-06-26 ES ES03742226T patent/ES2244361T1/es active Pending
- 2003-06-26 WO PCT/US2003/020154 patent/WO2004012742A1/en not_active Ceased
- 2003-06-26 AU AU2003281817A patent/AU2003281817A1/en not_active Abandoned
- 2003-06-26 BR BR0313546-2A patent/BR0313546A/pt not_active IP Right Cessation
- 2003-06-26 RU RU2005106234/14A patent/RU2322239C2/ru not_active IP Right Cessation
- 2003-06-26 EP EP03742226A patent/EP1539182A4/en not_active Withdrawn
- 2003-06-26 CN CNA038188260A patent/CN1674913A/zh active Pending
- 2003-06-26 CA CA002494211A patent/CA2494211A1/en not_active Abandoned
- 2003-07-07 TW TW092118474A patent/TW200410699A/zh unknown
- 2003-07-17 AR AR20030102575A patent/AR040599A1/es unknown
-
2005
- 2005-01-25 ZA ZA200500731A patent/ZA200500731B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR040599A1 (es) | 2005-04-13 |
| BR0313546A (pt) | 2005-07-12 |
| ZA200500731B (en) | 2006-08-30 |
| RU2005106234A (ru) | 2005-08-10 |
| KR20050026510A (ko) | 2005-03-15 |
| US20060166956A1 (en) | 2006-07-27 |
| AU2003281817A1 (en) | 2004-02-23 |
| MXPA05000773A (es) | 2005-04-19 |
| CN1674913A (zh) | 2005-09-28 |
| WO2004012742A1 (en) | 2004-02-12 |
| US20040127472A1 (en) | 2004-07-01 |
| PL375024A1 (en) | 2005-11-14 |
| DE03742226T1 (de) | 2006-03-09 |
| ES2244361T1 (es) | 2005-12-16 |
| JP2005535691A (ja) | 2005-11-24 |
| CA2494211A1 (en) | 2004-02-12 |
| EP1539182A1 (en) | 2005-06-15 |
| EP1539182A4 (en) | 2010-01-20 |
| RU2322239C2 (ru) | 2008-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Massin et al. | Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial | |
| CA2718161C (en) | Drug delivery to the anterior and posterior segments of the eye using eye drops | |
| US20030171320A1 (en) | Methods for treating ocular neovascular diseases | |
| WO2010125416A1 (en) | Drug delivery to the anterior and posterior segments of the eye | |
| BR112020010659A2 (pt) | uso de um antagonista do vegf para tratar disfunções oftalmológicas angiogênicas | |
| TW200410699A (en) | Use of ANECORTAVE acetate for the protection of visual acuity in patients with age related macular degeneration | |
| US20230089914A1 (en) | Compositions comprising axitinib and methods of treating ocular disorders | |
| US20240342202A1 (en) | Methods of Treating Retinal Vasculopathies | |
| US20050043220A1 (en) | Methods and compositions for treating macular degeneration | |
| JP2020532586A (ja) | 網膜血管性疾患の処置のためのａｎｇｉｏ−３ | |
| JP2016121163A (ja) | 眼内でのコルチコステロイド使用に伴う眼圧の発生を減少させる方法 | |
| Lee et al. | High dose intravitreal bevacizumab for refractory pigment epithelial detachment in age-related macular degeneration | |
| Shaikh et al. | Comparison between suprachoroidal triamcinolone and intravitreal triamcinolone acetonide in patients of resistant diabetic macular edema | |
| Yeniad et al. | Assessment of anterior chamber inflammation after intravitreal bevacizumab injection in different ocular exudative diseases | |
| Angunawela et al. | vitreous, Choroid, and retina | |
| Agarwal | An Interventional Follow Up Study of Resolution of Steroid Responsive Macular Edema After Intravitreal Triamcinolone Acetonide | |
| Sunaga et al. | Supplementary material 4 to: Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration | |
| AU2002363336A1 (en) | Methods for treating ocular neovascular diseases |